Pancreatic adenocarcinoma

BMJ (Online)

Volumn 344, Issue 7857, 2012, Pages

  Bond Smith, Giles ^a   Banga, Neal ^a   Hammond, Toby M ^b   Imber, Charles J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; CAPECITABINE PLUS GEMCITABINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANTIGEN DETECTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION BIOPSY; BACKACHE; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DYSPEPSIA; ENDOSCOPIC ECHOGRAPHY; HUMAN; INCIDENCE; JAUNDICE; NAUSEA; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STEATORRHEA; STOMACH EMPTYING; SURVIVAL RATE; SYMPTOMATOLOGY; VOMITING; ADENOCARCINOMA; MULTIMODALITY CANCER THERAPY; PANCREAS TUMOR; PATIENT SELECTION; RISK FACTOR;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PATIENT SELECTION; RISK FACTORS;

EID: 84862099291     PISSN: 17561833     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.e2476     Document Type: Review

References (37)

1. Singh SM, Longmire WP Jr, Reber HA. Surgical palliation for pancreatic cancer. The UCLA experience. Ann Surg 1990;212:132-9. (Pubitemid 20241036)
2. Singh SM, Reber HA. Surgical palliation for pancreatic cancer. Surg Clin North Am 1989;69:599-611. (Pubitemid 19158354)
3. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006;95:1474-82. (Pubitemid 44863349)
4. Anderson K, Mack TM, Silverman DT. Cancer of the pancreas. In: Schottenfeld D, Fraumeni JF Jr, eds. Cancer epidemiology and prevention. 3rd ed. Oxford University Press, 2006.
5. Cancer Research UK. Cancer mortality: UK statistics. 2009. http://info.cancerresearchuk. org/cancerstats/mortality.
6. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford) 2008;10:58-62. (Pubitemid 351298114)
7. Cancer Research UK. Pancreatic cancer: UK incidence statistics. 2011. http://info. cancerresearchuk.org/cancerstats/types/pancreas/incidence.
8. Elliss-Brookes L. Routes to diagnosis. National Cancer Intelligence Network, 2010. www. ncin.org.uk/publications/data-briefings/routes-to-diagnosis. aspx.
9. Gullo L, Tomassetti P, Migliori M, Casadei R, Marrano D. Do early symptoms of pancreatic cancer exist that can allow an earlier diagnosis? Pancreas 2001;22:210-3. (Pubitemid 32179179)
10. Watanabe I, Sasaki S, Konishi M, Nakagohri T, Inoue K, Oda T, et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 2004;28:160-5. (Pubitemid 38269776)
11. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504-11. (Pubitemid 41096638)
12. Maitra A, Adsay NV, Argani P, Iacobuzio-Donahue C, De Marzo A, Cameron JL, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 2003;16:902-12. (Pubitemid 37152020)
13. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53-5. (Pubitemid 11114676)
14. Valls C, Andía E, Sanchez A, Fabregat J, Pozuelo O, Quintero JC, et al. Dual-phase helical CT of pancreatic adenocarcinoma: assessment of resectability before surgery. AJR Am J Roentgenol 2002;178:821-6. (Pubitemid 34250214)
15. Shrikhande, S, Freiss H, Buchler M, eds. Surgery of pancreatic tumors. BI Publications Pvt Ltd, 2008.
16. Tabuchi T, Itoh K, Ohshio G, Kojima N, Maetani Y, Shibata T, et al. Tumor staging of pancreatic adenocarcinoma using early- and late-phase helical CT. AJR Am J Roentgenol 1999;173:375-80. (Pubitemid 29347362)
17. Iglesias Garcia J, Lariño Noia J, Domínguez Muñoz JE. Endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Rev Esp Enferm Dig 2009;101:631-8.
18. Kahl S, Malfertheiner P. Role of endoscopic ultrasound in the diagnosis of patients with solid pancreatic masses. Dig Dis 2004;22:26-31. (Pubitemid 39070144)
19. Chang KJ, Nguyen P, Erickson RA, Durbin TE, Katz KD. The clinical utility of endoscopic ultrasound-guided fine needle aspiration in the diagnosis and staging of pancreatic adenocarcinoma. Gastrointest Endosc 1997;45:387-93. (Pubitemid 27426180)
20. Müller MF, Meyenberger C, Bertschinger P, Schaer R, Marincek B. Pancreatic tumors: evaluation with endoscopic US, CT, and MR imaging. Radiology 1994;190:745-51. (Pubitemid 24071041)
21. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. Springer, 2002.
22. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27. (Pubitemid 38812419)
23. Reddy SK, Tyler DS, Pappas TN, Clary BM. Extended resection for pancreatic adenocarcinoma. Oncologist 2007;12:654-63. (Pubitemid 47036202)
24. Ramacciato G, Mercantini P, Petrucciani N, Giaccaglia V, Nigri G, Ravaioli M, et al. Does portal-superior mesenteric vein invasion still indicate irresectability for pancreatic carcinoma? Ann Surg Oncol 2009;16:817-25.
25. Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009;16:1736-44.
26. Chua T, Saxena A. Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg 2010;14:1442-52.
27. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267.
28. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. Ann Surg 1935;102:763-79.
29. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997;226:248-60.
30. McPhee JT, Hill JS, Whalen GF, Zayaruzny M, Litwin DE, Sullivan ME, et al. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 2007;246:246-53. (Pubitemid 47196522)
31. Kelly KJ, Greenblatt DY, Wan Y, Rettammel RJ, Winslow E, Cho CS, et al. Risk stratification for distal pancreatectomy utilizing ACS-NSQIP: preoperative factors predict morbidity and mortality. J Gastrointest Surg 2011;15:250-61.
32. Zhou W, Lv R, Wang X, Mou Y, Cai X, Herr I. Stapler vs suture closure of pancreatic remnant after distal pancreatectomy: a meta-analysis. Am J Surg 2010;200:529-36.
33. Briggs CD, Mann CD, Irving GR, Neal CP, Peterson M, Cameron IC, et al. Systematic review of minimally invasive pancreatic resection. J Gastrointest Surg 2009;13:1129-37.
34. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903. (Pubitemid 15040883)
35. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. (Pubitemid 38339364)
36. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.
37. Yang YM, Tian XD, Zhuang Y, Wang WM, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol 2005;11:2456-61. (Pubitemid 40667981)